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180 (135–219) min after methadone intake. QTc did not increase 
with increasing methadone concentrations, R2 = 0.0015.
Conclusion: Another route than renal and hemodialysis must 
eliminate methadone in these patients as only a small amount of 
methadone was lost in hemodialysate and urine. All values of serum-
methadone were comparable with those seen in patients with nor-
mal renal function after similar daily methadone doses. QTc tended 
to increase during hemodialysis. However, this increase was not 
concentration-dependent on methadone.
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Introduction: Different pharmaceutical formulations of the car-
diovascular drug, calcium antagonist, diltiazem may reflect in its 
different bioavailability, that may subsequently influence the pharma-
cological effects. The primary purpose of the study was to compare 
the cardiovascular activities of 2 different modified-release formula-
tions of diltiazem: gelatine capsules with micropellets and film-coated 
tablets. Secondary, we would like to consider if the pharmacodynamic 
data may be useful in concluding the therapeutic equivalence of dif-
ferent diltiazem formulations.
Patients (or Materials) and Methods: The study was conducted on 
a group of healthy, male subjects that participated in a randomized, 
2-way cross-over bioavailability trial of 2 diltiazem MR formulation 
after single and multiple doses of 120 mg. During the course of the 
study standard bioavailability parameters (AUCt, AUCinf, Cmax, 
Cmin) for both formulations were calculated. Bioequivalence tasting 
was based on Shuirmann’s procedure. Pharmacological effects were 
evaluated after single- and multiple-dose administration. Blood pres-
sure, ECG parameters (QTc, PQ) and heart rate variability (HRV) 
were measured continuously (ECG Holter monitoring) up to 24 
hours after administration and analyzed at the same time points as 
pharmacokinetic samples to plot the effect-time profile. Classical 
HRV analysis in time and frequency domains was conducted and 
several components of HRV estimated (RR, RMS, SDNN, PNN, 
LF, HF and LF/HF). Mean values at each time point and calculated 
effect parameters (AUEC, Emax, TEmax) were compared statistically 
between formulations (t-test, p< 0.05). Pharmacological data were 
correlated with pharmacokinetic parameters.
Results: Bioavailability analysis concluded inequivalence (CI for 
Cmax(single): 0.78–0.95). In pharmacodynamic analysis the only 
statistically significant difference was observed after multiple doses of 
diltiazem for the extend of PQ effect (AUEC0-8 [ms*h]; P = 0.0289). 
Differences for the other calculated BP, ECG and HRV parameters were 
statistically insignificant (p ≥ 0.05), although distinct diversity have 
been observed. Bioequivalence couldn’t be concluded in the basis of 
PD data. High variability of values was observed (CV% > 50%–60%).
Conclusion: Differences in the most of tested pharmacodynamic 
parameters were found between 2 diltiazem formulations. Although 
most of them were statistically insignificant they may indicate the 
diversity of 2 tested modified-release oral diltiazem formulations in 
respect of bioavailability and pharmacodynamics. Because of their 
high variability cardiovascular parameters can be used in the estima-
tion of therapeutic equivalence only in limited range.
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Introduction: The objectives of this study were to determine the 
pharmacokinetics (PK) and safety of single-dose sugammadex (16 
mg/kg) in healthy Chinese adult volunteers. The 16-mg/kg dose was 
chosen because this is the highest recommended dose for use in clini-
cal practice, for immediate reversal of NMB.
Patients (or Materials) and Methods: In this open-label study, 
healthy Chinese subjects received intravenous (IV) sugammadex 
(16 mg/kg) as a 10-second bolus infusion. Blood samples were 
collected pre-sugammadex and at regular intervals up to 24 hours 
post-sugammadex for PK assessment. Safety was also evaluated, 
via adverse events (AEs), vital signs, ECG, and laboratory param-
eters.
Results: Twelve subjects were included (6 male; 6 female). 
Geometric mean (CV%) weight was 58.3 (3.7%) kg and 53.6 
(9.8%) kg for males and females, respectively. The main pharma-
cokinetic parameters are shown in the Table. After the 16-mg/kg 
sugammadex dose, plasma sugammadex concentrations showed 
a polyexponential decline over time, indicating 2 to 3 compart-
ments, with an overall geometric mean (CV) terminal half-life 
(t½) of 145 (17.9%) minutes (139 [17.7%]) minutes for males; 
152 [18.6%] minutes for females). No influence of gender on the 
PK of sugammadex was observed. Three subjects experienced an 
AE (dysgeusia of mild intensity in all cases), which was consid-
ered possibly or probably related to sugammadex. Dysgeusia is 
a known adverse drug reaction in healthy conscious subjects. 
There were no clinically significant changes in vital signs, ECG, 
or laboratory parameters.
Conclusion: After a single IV bolus infusion dose of sugammadex 16 
mg/kg in healthy Chinese subjects, peak sugammadex concentration 
was 197 μ g/mL, clearance was 99.7 mL/min, and volume of distribu-
tion was 10.5 L. No influence of gender on the PK of sugammadex 
was observed. Overall between-subject variability on clearance and 
volume of distribution was ~10%. Sugammadex was generally well 
tolerated in Chinese volunteers.
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Table.  Geometric mean (CV %) pharmacokinetic parameters for 
sugammadex 16 mg/kg in Chinese subjects.
male (n = 6) Female (n = 6) Total (n = 12)
Tmax, min
a> 2.0 (2.0–3.0) Tmax, mina 3.0 (2.0–3.0) Tmax, mina 2.5 (2.0–3.0)
Cmax, µg/mL 214 (27.7%) Cmax, µg/mL 182 (10.6%) Cmax, µg/mL 197 (21.7%)
CL, mL/min 104 (12.5%) CL, mL/min 95.8 (12.4%) CL, mL/min 99.7 (12.6%)
Vss, L 10.7 (10.7%) Vss, L 10.3 (7.4%) Vss, L 10.5 (9.0%)
aValues given as median (range). Tmax = time to maximum observed concentration;  
Cmax = maximum observed concentration; CL = clearance, Vss = volume of distribution 
at equilibrium.
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Introduction: Major problem for diabetic patients represents dam-
age of blood vessels and the oxidative stress of the brain cells due to 
increased concentration of free radicals and poor nutrition of brain 
cells. Gliclazide has antioxidative properties and poor blood brain 
barrier (BBB) penetration. Bile acids are known for their hypogly-
cemic effect and as prooters of drug penetration across biological 
membranes.
Aim: The aim of this study is to investigate whether the bile acid 
(deoxycholic acid) can change the permeation of gliclazide, through 
the blood brain barrier of a rat model type-1 diabetes.
Patients (or Materials) and Methods: Twenty-four male Wistar rats 
were randomly allocated to 4 groups, of which 2 were given alloxan 
intraperitoneally (100 mg/kg) to induce diabetes. One diabetic group 
and 1 healthy group were given a bolus gliclazide intra-arterially (20 
mg/kg), while the other 2 groups apart from gliclazide got deoxy-
cholic acid (4 mg/kg) subcutaneously. Blood samples were collected 
30, 60, 150, and 240 seconds after dose, brain tissues were immedi-
ately excised, and blood glucose and gliclazide concentrations were 
measured.
Results: Penetration of gliclazide in groups without deoxycholic 
acid pretreatment was increased in diabetic animals compared with 
healthy animals. Also in both, healthy and diabetic animals, deoxy-
cholic acid increased the permeation of gliclazide through that in 
BBB. Deoxycholic acid pretreatment also changed the pattern of 
blood glucose level increase after gliclazide application in diabetic 
as well as in healthy animals.
Conclusion: Deoxycholic acid promotes gliclazide penetration across 
BBB in diabetic and in healthy animals. In addition, deoxycholic 
acid alters some pharmacokinetic properties of gliclazide in both 
healthy and diabetic rats. Thus, deoxycholic acid should be more 
investigated in the treatment of diabetes mellitus and as permea-
tion promoter of lipophilic molecules through BBB as well as other 
biological membranes.
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Introduction: Paracetamol (APAP) is recommended as the initial 
pharmacologic treatment of choice for the management of osteoar-
thritis (OA). However, inadequate compliance with the prescribed 
regimen can lead to reduced efficacy. This may in turn prompt 
patients to switch to other analgesics with increased safety risks. 
Panadol 1 g sustained release (P12) tablet is a twice-daily sustained 
released formulation that provides 4 g of paracetamol per day that 
could dramatically enhance patient’s compliance and reduce the pos-
sibility of switching to less well-tolerated drugs. The main objective of 
this investigation was to evaluate the maximum paracetamol concen-
tration in plasma (Cmax) after a twice-daily dosing (BID) regimen with 
P12 compared with the currently marketed immediate-release (IR) 
formulation. In addition, we apply pharmacokinetic-pharmacody-
namic concepts to assess the time that APAP levels remain above the 
minimum effective concentration (MEC) and evaluate the potential 
impact of differences in exposure between the 2 formulations on the 
risk of hepatotoxicity in osteoarthritis patients.
Patients (or Materials) and Methods: A population PK model was 
developed using data from 3 Phase I studies and 1 study in patients 
with type 2 diabetes to explore the effects of demographic covariates. 
Using the nomogram line as reference to assess the risk of APAP-
induced hepatotoxicity, different dosing scenarios were simulated 
taking into account the effects of age, sex, and body weight. Peak 
concentrations (Cmax) were used as measure of interest to assess the 
probability of liver toxicity. APAP concentrations were assumed to 
be the primary driver of toxicity.
Results: Our results show that there is no difference in the risk 
of hepatotoxicity between the regimens when APAP is taken at 
therapeutic doses or after an unintentional overdose of 4 tablets. 
After an unintentional overdose with 10 tablets, hepatotoxicity 
is predicted for 1 of 10,000 patients taking the IR formulation 
under fasted conditions and for none of the patients taking the 
P12 formulation. After overdose with 10 tablets, patients with 
low body weight are likely to exceed the toxic threshold by no 
more than 0% to 0.94% for the IR and by 0.04% to 0.15% for 
P12 formulation.
Conclusion: In conclusion, the risk of hepatotoxicity after BID dos-
ing appears to be similar to the standard regimen. Our analysis also 
reveals that the proportion of patients who stay above the MEC is 
higher for P12 when APAP is taken under fasting conditions. These 
results illustrate the relevance of clinical trial simulations before the 
implementation of a clinical trial protocol. Our approach illustrates 
what should be considered best-practice in the evaluation of drug 
safety in late clinical development.
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Introduction: In the current situation of worldwide spreading of mul-
tidrug-resistant A baumannii and only a few effective antimicrobial 
agents currently available, sulbactam is a potentially useful alterna-
tive treatment option for this pathogen. This agent is characterized by 
time-dependent antimicrobial activity and the exposure time during 
which the free drug concentration remains above the MIC (T> MIC) 
is the pharmacokinetic/pharmacodynamic (PK/PD) index that best 
correlates with efficacy.
Objectives: The aims of the study were to: (1) reveal a population 
pharmacokinetic (PK) model to describe the disposition of sulbactam; 
and (2) assess the efficacy of various dosage regimens of sulbactam 
in achieving the probability of target attainment (PTA) of this agent 
over a range of MICs.
